Loading...

Imke Bartelink, PhD

TitlePostdoctoral Scholar
SchoolUCSF School of Medicine
DepartmentMedicine
Address1450 Third St
San Francisco CA 94158
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, Bredius RG, Egberts AC, Bierings M, Kletzel M, Shaw PJ, Nath CE, Hempel G, Ansari M, Krajinovic M, Théorêt Y, Duval M, Keizer RJ, Bittencourt H, Hassan M, Güngör T, Wynn RF, Veys P, Cuvelier GD, Marktel S, Chiesa R, Cowan MJ, Slatter MA, Stricherz MK, Jennissen C, Long-Boyle JR, Boelens JJ. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 2016 Nov; 3(11):e526-e536. PMID: 27746112.
      View in: PubMed
    2. Long-Boyle JR, Savic R, Yan S, Bartelink I, Musick L, French D, Law J, Horn B, Cowan MJ, Dvorak CC. Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use. Ther Drug Monit. 2015 Apr; 37(2):236-45. PMID: 25162216; PMCID: PMC4342323 [Available on 04/01/16].
    3. Admiraal R, van Kesteren C, Jol-van der Zijde CM, van Tol MJ, Bartelink IH, Bredius RG, Boelens JJ, Knibbe CA. Population pharmacokinetic modeling of Thymoglobulin(®) in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosing. Clin Pharmacokinet. 2015 Apr; 54(4):435-46. PMID: 25466602.
      View in: PubMed
    4. Bartelink IH, Savic RM, Dorsey G, Ruel T, Gingrich D, Scherpbier HJ, Capparelli E, Jullien V, Young SL, Achan J, Plenty A, Charlebois E, Kamya M, Havlir D, Aweeka F. The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda. Pediatr Infect Dis J. 2015 Mar; 34(3):e63-70. PMID: 25742090; PMCID: PMC4351793 [Available on 03/01/16].
    5. Vreeman RC, Nyandiko WM, Liechty EA, Busakhala N, Bartelink IH, Savic RM, Scanlon ML, Ayaya SO, Blaschke TF. Impact of adherence and anthropometric characteristics on nevirapine pharmacokinetics and exposure among HIV-infected Kenyan children. J Acquir Immune Defic Syndr. 2014 Nov 1; 67(3):277-86. PMID: 25140906.
      View in: PubMed
    6. Bartelink I, van Reij EM, Gerhardt CE, van Maarseveen EM, de Wildt A, Versluys B, Lindemans CA, Bierings MB, Boelens JJ. Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity. Biol Blood Marrow Transplant. 2014 Mar; 20(3):345-53. PMID: 24315842.
      View in: PubMed
    7. Kerl K, Diestelhorst C, Bartelink I, Boelens J, Trame MN, Boos J, Hempel G. Evaluation of effects of busulfan and DMA on SOS in pediatric stem cell recipients. Pediatr Blood Cancer. 2014 Feb; 61(2):306-11. PMID: 24174393.
      View in: PubMed
    8. Bartelink IH, Savic RM, Mwesigwa J, Achan J, Clark T, Plenty A, Charlebois E, Kamya M, Young SL, Gandhi M, Havlir D, Cohan D, Aweeka F. Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda. J Clin Pharmacol. 2014 Feb; 54(2):121-32. PMID: 24038035; PMCID: PMC3933454.
    9. Trame MN, Bartelink IH, Boos J, Boelens JJ, Hempel G. Population pharmacokinetics of dimethylacetamide in children during standard and once-daily IV busulfan administration. Cancer Chemother Pharmacol. 2013 Nov; 72(5):1149-55. PMID: 24036908.
      View in: PubMed
    10. Savic RM, Cowan MJ, Dvorak CC, Pai SY, Pereira L, Bartelink IH, Boelens JJ, Bredius RG, Wynn RF, Cuvelier GD, Shaw PJ, Slatter MA, Long-Boyle J. Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013 Nov; 19(11):1608-14. PMID: 24029650; PMCID: PMC3848313.
    11. Bartelink IH, Wolfs T, Jonker M, de Waal M, Egberts TC, Ververs TT, Boelens JJ, Bierings M. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. Antimicrob Agents Chemother. 2013 Jan; 57(1):235-40. PMID: 23114771; PMCID: PMC3535953.
    12. Bartelink IH, Belitser SV, Knibbe CA, Danhof M, de Pagter AJ, Egberts TC, Boelens JJ. Immune reconstitution kinetics as an early predictor for mortality using various hematopoietic stem cell sources in children. Biol Blood Marrow Transplant. 2013 Feb; 19(2):305-13. PMID: 23092812.
      View in: PubMed
    13. Bartelink IH, van Kesteren C, Boelens JJ, Egberts TC, Bierings MB, Cuvelier GD, Wynn RF, Slatter MA, Chiesa R, Danhof M, Knibbe CA. Predictive performance of a busulfan pharmacokinetic model in children and young adults. Ther Drug Monit. 2012 Oct; 34(5):574-83. PMID: 22972539.
      View in: PubMed
    14. Bartelink IH, Boelens JJ, Bredius RG, Egberts AC, Wang C, Bierings MB, Shaw PJ, Nath CE, Hempel G, Zwaveling J, Danhof M, Knibbe CA. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin Pharmacokinet. 2012 May 1; 51(5):331-45. PMID: 22455797.
      View in: PubMed
    15. Beers E, van Puijenbroek EP, Bartelink IH, van der Linden CM, Jansen PA. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatraemia associated with valproic Acid: four case reports from the Netherlands and a case/non-case analysis of vigibase. Drug Saf. 2010 Jan 1; 33(1):47-55. PMID: 20000866.
      View in: PubMed
    16. Kerckhoffs AP, Akkermans LM, de Smet MB, Besselink MG, Hietbrink F, Bartelink IH, Busschers WB, Samsom M, Renooij W. Intestinal permeability in irritable bowel syndrome patients: effects of NSAIDs. Dig Dis Sci. 2010 Mar; 55(3):716-23. PMID: 19255843.
      View in: PubMed
    17. Bartelink IH, Bredius RG, Belitser SV, Suttorp MM, Bierings M, Knibbe CA, Egeler M, Lankester AC, Egberts AC, Zwaveling J, Boelens JJ. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. Biol Blood Marrow Transplant. 2009 Feb; 15(2):231-41. PMID: 19167683.
      View in: PubMed
    18. Zwaveling J, Press RR, Bredius RG, van Derstraaten TR, den Hartigh J, Bartelink IH, Boelens JJ, Guchelaar HJ. Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients. Ther Drug Monit. 2008 Aug; 30(4):504-10. PMID: 18641537.
      View in: PubMed
    19. Bartelink IH, Bredius RG, Ververs TT, Raphael MF, van Kesteren C, Bierings M, Rademaker CM, den Hartigh J, Uiterwaal CS, Zwaveling J, Boelens JJ. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008 Jan; 14(1):88-98. PMID: 18158965.
      View in: PubMed
    20. van Kooij B, Fijnheer R, de Boer J, ten Dam-van Loon N, Bartelink I, Roest M, Rothova A. A randomized, masked, cross-over trial of lisinopril for inflammatory macular edema. Am J Ophthalmol. 2006 Apr; 141(4):646-51. PMID: 16564798.
      View in: PubMed
    21. Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet. 2006; 45(11):1077-97. PMID: 17048973.
      View in: PubMed
    22. Thomas HD, Porter DJ, Bartelink I, Nobbs JR, Cole M, Elliott S, Newell DR, Calvert AH, Highley M, Boddy AV. Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide. Br J Clin Pharmacol. 2002 Jan; 53(1):83-91. PMID: 11849199; PMCID: PMC1874557.
    Back to TOP